Stockreport

Bristol-Myers' Liso-Cel Given Priority Review, Ability To Change Scope Of Treatment [Seeking Alpha]

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF Summary The FDA accepted the BLA for liso-cel to treat patients with relapsed/refractory diffuse large B-cell lymphoma. A PDUFA date for liso-cel for the treatment of pa [Read more]